Home › Compare › ANTH vs VYM

ANTH vs VYM: Dividend Comparison 2026

ANTH yields 2000000.00% · VYM yields 2.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANTH wins by $4.879226400974806e+39M in total portfolio value
10 years
ANTH
ANTH
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full ANTH calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.41%
Share price
$145.48
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$278.55
Full VYM calculator →

Portfolio growth — ANTH vs VYM

📍 ANTH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANTHVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANTH + VYM cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ANTH pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANTH
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
VYM
Annual income on $10K today (after 15% tax)
$205.23/yr
After 10yr DRIP, annual income (after tax)
$236.77/yr
At 15% tax rate, ANTH beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANTH + VYM for your $10,000?

ANTH: 50%VYM: 50%
100% VYM50/50100% ANTH
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ANTH right now

ANTH
Analyst Ratings
8
Buy
3
Hold
1
Sell
Consensus: Buy
Altman Z
-78.1
Piotroski
0/9
VYM
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANTH buys
0
VYM buys
0
No recent congressional trades found for ANTH or VYM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANTHVYM
Forward yield2000000.00% ✓2.41%
Annual dividend / share$2.00$3.51 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.879226400974806e+39M$27.8K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$278.55
Total dividends collected$4.879195005460081e+39M ✓$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ANTH vs VYM ($10,000, DRIP)

YearANTH PortfolioANTH Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,151$241.44+$200.00M → ANTH
2$3,738,731,768,458$3,738,517,757,009.35$12,413$246.79+$3738731.76M → ANTH
3$65,315,062,866,930,490$65,311,062,423,938,240.00$13,794$251.79+$65315062866.92M → ANTH
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$15,306$256.47+$1066400830062625.00M → ANTH
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$16,960$260.84+$16272182796453826560.00M → ANTH
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$18,768$264.92+$2.3205424011366188e+23M → ANTH
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$20,745$268.71+$3.0927990661046884e+27M → ANTH
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$22,905$272.24+$3.8524105697352695e+31M → ANTH
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$25,265$275.51+$4.484688260147987e+35M → ANTH
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$27,842$278.55+$4.879226400974806e+39M → ANTH

ANTH vs VYM: Complete Analysis 2026

ANTH — Stock

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Full ANTH Calculator →

VYM — ETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this ANTH vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANTH vs SCHDANTH vs JEPIANTH vs OANTH vs KOANTH vs MAINANTH vs VIGANTH vs DGROANTH vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.